Kainova Therapeutics is a clinical-stage biopharmaceutical company focused on developing GPCR-modulating therapies for immuno-oncology and inflammation
Kainova Therapeutics is a clinical-stage biopharmaceutical company focused on developing GPCR-modulating therapies for immuno-oncology and inflammation. They have a robust pipeline including unique clinical-stage therapies such as DT-7012, an anti-CCR8 antibody, and DT-9046, a biased antagonist of PAR2.